Abstract 435TiP
Background
Treatment with PD-L1 or PD-1 targeting antibodies is a cornerstone in cancer therapy, but not all patients benefit from these drugs. For most indications, the current reference biomarker is PD-L1 expression in a tumor biopsy, but this method has several disadvantages. Molecular imaging, such as PET/CT using receptor-specific radiotracers, offers non-invasive, real-time visualization of treatment targets. Previous trials have explored a few PD-L1/PD-1 radiotracers but lacked a systematic approach focused on a single tumor type and standardized clinical management.
Trial design
The MIMIR-trial (EU CT 2022-500808-21-00, NCT05742269) involves newly diagnosed mTNBC patients planned for first-line systemic treatment. Participants undergo a PD-L1 PET/CT scan with [89Zr]Zr-atezolizumab followed by a biopsy, with results guiding subsequent treatment with chemotherapy (carboplatin and nab-paclitaxel), combined with atezolizumab based on PD-L1 status as determined by IHC and/or PET. Treatment effectiveness is assessed bi-monthly, and therapy is continued until disease progression or unmanageable toxicity. The primary aim is to determine the statistical concordance (Cohen’s kappa coefficient) between PD-L1 status by PET and IHC. To target a kappa of 0.80 with a precision of +/- 0.15, 64 patients are required in this study. Secondary objectives include evaluating the predictive value of PD-L1 PET for treatment response and development of immunotherapy-mediated toxicity. Tissue, feces, and blood samples are collected for further translational analysis. The trial is ongoing at Karolinska University Hospital in Stockholm, Sweden, with three patients enrolled so far. An additional cohort of patients with non small cell lung cancer will be opened during Q3-4 2024.
Clinical trial identification
EU CT 2022-500808-21-00, NCT05742269.
Editorial acknowledgement
Legal entity responsible for the study
Karolinska University hospital, Region Stockholm, Sweden.
Funding
Roche Sweden AB.
Disclosure
J. Bergh: Non-Financial Interests, Personal, Advisory Board: stratipath. All other authors have declared no conflicts of interest.
Resources from the same session
403P - Stemness-targeted therapies to inhibit cancer cell plasticity in triple negative breast cancer
Presenter: Andrew Takchi
Session: Poster session 15
404P - Real-world analysis on molecular targeted therapy recommendations and attainment rates in cancer gene panel testing for metastatic breast cancer
Presenter: Hiroshi Tada
Session: Poster session 15
405P - HRD biomarkers in blood samples from BRCA1/BRCA2-associated advanced breast cancer (BC) patients (pts)
Presenter: Violeta Serra
Session: Poster session 15
406P - Genomic landscape of endocrine therapy (ET)-resistant BRCA1/2 and PALB2 altered metastatic breast cancer (mBC)
Presenter: Abeid Omar
Session: Poster session 15
407P - Genomic profiling and prediction role of the molecular tumor burden index in advanced HR+HER2- breast cancer
Presenter: Xuenan Peng
Session: Poster session 15
408P - Characterizing the genomic landscape of breast cancer in an Irish cohort of patients
Presenter: Georgia Thodi
Session: Poster session 15
409P - Biological tumor traits predicting late recurrence in premenopausal breast cancer patients: Insights from the STO-5 trial with 20-year follow-up
Presenter: Jo De Vos
Session: Poster session 15
410P - Breast cancer lighthouse non-interventional hybrid real-world study: Molecular characterization and 2-year effectiveness data
Presenter: Angela Margarida Nogal Dias
Session: Poster session 15
412P - Exploratory circulating tumor DNA (ctDNA) analysis in HR+/HER2- metastatic breast cancer (mBC) and impact on clinical efficacy with sacituzumab govitecan (SG) in TROPiCS-02
Presenter: Hope Rugo
Session: Poster session 15